Figure 1: Examples of clinically used anti-multiple myeloma drugs

Figure 2: Chemical structures of some COXs inhibitors and their Selectivity Index (SI). SI corresponds to the ratio COX-2 IC₅₀/COX-1 IC₅₀. SI values higher than 1 means that the compound is a selective COX-1 inhibitor [8-10]

Figure 3: Adjusted image of Western blotting experiments depicting the expression of COX-1 and COX-2 isoenzymes determined by Western blotting. Original gel blots are reported in Supplementary Materials

Figure 4: Hypotesis of COX activation in a BMSCs milieu, in turn permissive for MM cells proliferation, angiogenesis inducer, metastasis and drug resistrance development. COXs structures used are PDB: 6Y3C for COX-1 [46] and PDB:1CVU for COX-2 [47]

Figure 5: Expression of COXs in BMSCs upon treatment with mofezolac alone or in combination with BRZ, DEX or THA. Cells were incubated for 48 hours with (+) or without (-) 100 μM MOF, 100 μM CEL, 100 μM DEX, 100 μM THA, 300 nM BRZ. 30 μg of protein extract were applied to Western blot. The protein level of β-actin was used as the loading control. HEK-293 COX-1 cells are the positive control. Original blots are in the Supporting Materials

Figure 6: Anti-proliferative activity of anti-MM drugs alone or added with COXs inhibitors on hBMSCs growth